Cencora, Inc. (NYSE:COR) CEO Steven H. Collis Sells 10,754 Shares

Cencora, Inc. (NYSE:COR) CEO Steven H. Collis sold 10,754 shares of the company’s stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $237.48, for a total transaction of $2,553,859.92. Following the transaction, the chief executive officer now owns 285,088 shares in the company, valued at approximately $67,702,698.24. The sale was disclosed in a filing with the SEC, which is available at this link.

Cencora Trading Up 0.1 %

Shares of NYSE:COR opened at $238.60 on Thursday. The firm has a market capitalization of $47.60 billion, a price-to-earnings ratio of 25.99, a price-to-earnings-growth ratio of 1.79 and a beta of 0.45. The business’s 50 day moving average price is $237.53 and its 200-day moving average price is $214.64. The company has a debt-to-equity ratio of 3.94, a current ratio of 0.88 and a quick ratio of 0.52. Cencora, Inc. has a 1 year low of $163.37 and a 1 year high of $246.75.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $3.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.86 by $0.42. The business had revenue of $72.25 billion for the quarter, compared to the consensus estimate of $68.81 billion. Cencora had a net margin of 0.69% and a return on equity of 323.23%. During the same period last year, the firm posted $2.71 earnings per share. On average, equities research analysts forecast that Cencora, Inc. will post 13.43 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 26th. Shareholders of record on Friday, February 9th were paid a dividend of $0.51 per share. This is a positive change from Cencora’s previous quarterly dividend of $0.24. This represents a $2.04 annualized dividend and a yield of 0.85%. The ex-dividend date of this dividend was Thursday, February 8th. Cencora’s payout ratio is 22.22%.

Hedge Funds Weigh In On Cencora

Hedge funds and other institutional investors have recently made changes to their positions in the company. Trilogy Capital Inc. acquired a new position in Cencora in the 1st quarter valued at $312,000. Iron Horse Wealth Management LLC acquired a new stake in shares of Cencora in the first quarter valued at about $64,000. Baker Ellis Asset Management LLC purchased a new position in shares of Cencora in the first quarter worth about $481,000. Grimes & Company Inc. purchased a new position in shares of Cencora in the first quarter worth about $291,000. Finally, Hennion & Walsh Asset Management Inc. acquired a new position in Cencora during the first quarter worth about $1,862,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Leerink Partnrs reissued an “outperform” rating on shares of Cencora in a research report on Monday, February 26th. Mizuho increased their price objective on Cencora from $192.00 to $224.00 and gave the company a “neutral” rating in a report on Monday, February 5th. SVB Leerink assumed coverage on Cencora in a research report on Monday, February 26th. They issued an “outperform” rating and a $261.00 target price on the stock. Barclays assumed coverage on shares of Cencora in a research report on Wednesday, January 3rd. They set an “overweight” rating and a $242.00 price target for the company. Finally, StockNews.com raised shares of Cencora from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 1st. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $218.22.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.